Processa Pharmaceuticals, Inc.

NasdaqCM:PCSA Rapporto sulle azioni

Cap. di mercato: US$3.7m

Processa Pharmaceuticals Crescita futura

Future criteri di controllo 0/6

Processa Pharmaceuticals's earnings are forecast to decline at 9.6% per annum. EPS is expected to grow by 53.4% per annum.

Informazioni chiave

-9.6%

Tasso di crescita degli utili

53.4%

Tasso di crescita dell'EPS

Pharmaceuticals crescita degli utili23.7%
Tasso di crescita dei ricavin/a
Rendimento futuro del capitale proprion/a
Copertura analitica

Low

Ultimo aggiornamento03 Oct 2024

Aggiornamenti recenti sulla crescita futura

Recent updates

We Think Processa Pharmaceuticals (NASDAQ:PCSA) Needs To Drive Business Growth Carefully

Dec 12
We Think Processa Pharmaceuticals (NASDAQ:PCSA) Needs To Drive Business Growth Carefully

Will Processa Pharmaceuticals (NASDAQ:PCSA) Spend Its Cash Wisely?

Oct 20
Will Processa Pharmaceuticals (NASDAQ:PCSA) Spend Its Cash Wisely?

Processa Pharmaceuticals GAAP EPS of $0.53 beats by $0.73

Aug 12

We Think Processa Pharmaceuticals (NASDAQ:PCSA) Needs To Drive Business Growth Carefully

Jul 07
We Think Processa Pharmaceuticals (NASDAQ:PCSA) Needs To Drive Business Growth Carefully

We're Not Very Worried About Processa Pharmaceuticals' (NASDAQ:PCSA) Cash Burn Rate

Jan 20
We're Not Very Worried About Processa Pharmaceuticals' (NASDAQ:PCSA) Cash Burn Rate

Processa Pharmaceuticals (NASDAQ:PCSA) Is In A Good Position To Deliver On Growth Plans

Aug 26
Processa Pharmaceuticals (NASDAQ:PCSA) Is In A Good Position To Deliver On Growth Plans

Processa Pharmaceuticals (PCSA) Presents At LD Micro Invitations XI Virtual Conference - Slideshow

Jun 15

What Percentage Of Processa Pharmaceuticals, Inc. (NASDAQ:PCSA) Shares Do Insiders Own?

Mar 15
What Percentage Of Processa Pharmaceuticals, Inc. (NASDAQ:PCSA) Shares Do Insiders Own?

Processa Pharmaceuticals: Multiple Shots On Goal With Total TAM Of $8B - Worth A Look

Jan 29

How Many Processa Pharmaceuticals, Inc. (NASDAQ:PCSA) Shares Did Insiders Buy, In The Last Year?

Jan 20
How Many Processa Pharmaceuticals, Inc. (NASDAQ:PCSA) Shares Did Insiders Buy, In The Last Year?

Previsioni di crescita degli utili e dei ricavi

NasdaqCM:PCSA - Stime future degli analisti e dati finanziari passati (USD Millions )
DataRicaviGuadagniFlusso di cassa liberoLiquidità dell'operazioneAvg. Numero di analisti
12/31/2025N/A-13N/AN/A1
12/31/2024N/A-12N/AN/A1
9/30/2024N/A-12-11-11N/A
6/30/2024N/A-10-9-9N/A
3/31/2024N/A-10-8-8N/A
12/31/2023N/A-11-8-8N/A
9/30/2023N/A-22-8-8N/A
6/30/2023N/A-26-10-10N/A
3/31/2023N/A-28-10-10N/A
12/31/2022N/A-27-10-10N/A
9/30/2022N/A-18-10-10N/A
6/30/2022N/A-15-8-8N/A
3/31/2022N/A-13-8-8N/A
12/31/2021N/A-11-9-9N/A
9/30/2021N/A-23-8-8N/A
6/30/2021N/A-23-7-7N/A
3/31/2021N/A-20-5-5N/A
12/31/2020N/A-19-3-3N/A
9/30/2020N/A-6-1-1N/A
6/30/2020N/A-4-2-2N/A
3/31/2020N/A-4-3-3N/A
12/31/2019N/A-4-3-3N/A
9/30/2019N/A-3-3-3N/A
6/30/2019N/A-3-3-3N/A
3/31/2019N/A-3-3-3N/A
12/31/2018N/A-4-4-4N/A
9/30/2018N/A-4-4-4N/A
6/30/2018N/A-4N/A-4N/A
3/31/2018N/A-3N/A-3N/A
12/31/2017N/A-2N/A-2N/A
12/31/2016N/A-2N/A-2N/A

Previsioni di crescita futura degli analisti

Guadagni vs tasso di risparmio: PCSA is forecast to remain unprofitable over the next 3 years.

Guadagni vs Mercato: PCSA is forecast to remain unprofitable over the next 3 years.

Guadagni ad alta crescita: PCSA is forecast to remain unprofitable over the next 3 years.

Ricavi vs Mercato: Insufficient data to determine if PCSA's revenue is forecast to grow faster than the US market.

Ricavi ad alta crescita: PCSA is forecast to have no revenue next year.


Previsioni di crescita dell'utile per azione


Rendimento futuro del capitale proprio

ROE futuro: Insufficient data to determine if PCSA's Return on Equity is forecast to be high in 3 years time


Scoprire le aziende in crescita